# A Single Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Participants With Renal Insufficiency (MK-4618-014)

> **NCT01628042** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 32 (actual)

## Conditions studied

- Overactive Bladder

## Interventions

- **DRUG:** Vibegron 100 mg

## Key facts

- **NCT ID:** NCT01628042
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07-16
- **Primary completion:** 2013-01-25
- **Final completion:** 2013-01-25
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2018-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01628042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01628042, "A Single Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Participants With Renal Insufficiency (MK-4618-014)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01628042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*